RNS

RNS Number : 3519E MaxCyte, Inc. 26 February 2024   TR-1: N otification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)   i 1a. Identity of the issuer or the underlying issuer of existing shares to which
Feb 26, 2024
RNS Number : 6743C MaxCyte, Inc. 09 February 2024   MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences   ROCKVILLE, MD , February 9, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT ), a leading, cell-engineering
Feb 09, 2024
RNS Number : 7033B MaxCyte, Inc. 01 February 2024   MaxCyte, Inc.   (" MaxCyte " or the "Company")   Total Voting Rights   ROCKVILLE, Maryland  - 1 February 2024 :  MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform
Feb 01, 2024
RNS Number : 4333B MaxCyte, Inc. 31 January 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD , January 31, 2024 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Jan 31, 2024
RNS Number : 4077B MaxCyte, Inc. 30 January 2024   TR-1:   Notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)   i 1a. Identity of the issuer or the underlying issuer of existing shares to which
Jan 30, 2024
RNS Number : 3812B MaxCyte, Inc. 30 January 2024           MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers   Wugen to use MaxCyte's Flow Electroporation®
Jan 30, 2024
RNS Number : 2701B MaxCyte, Inc. 29 January 2024   TR-1: Notification   of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)   i 1a. Identity of the issuer or the underlying issuer of existing shares to which
Jan 29, 2024
RNS Number : 1340B MaxCyte, Inc. 29 January 2024         MaxCyte announces filing of Form 8-K   ROCKVILLE, MD , January 29, 2024   -   MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development
Jan 29, 2024
RNS Number : 6275A MaxCyte, Inc. 23 January 2024     MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs   Imugene using MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support azer-cel - a potential first-in-class allogeneic CD19
Jan 23, 2024
RNS Number : 0139Z MaxCyte, Inc. 09 January 2024            MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results   ROCKVILLE, MD , January 9, 2024   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
Jan 09, 2024